Table 1 Patient characteristics
From: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
Total no. of patients | 24 |
|---|---|
Gender | |
Male | 10 (42%) |
Female | 14 (58%) |
Age (years) | |
Median | 59.2 |
Range | 19–83 |
Stage of disease | |
Metastatic | 24 (100%) |
American Joint Committee on Cancer | |
Stage III | 16 (67%) |
Stage IV | 8 (33%) |
Sites of metastases | |
Cutaneous | 2 (8%) |
Soft tissue | 22 (92%) |
Visceral | 4 (17%) |
